In response to the escalating challenges posed by the high drug resistance of rapidly growing mycobacteria (RGM), a collaborative team from the Qingdao Institute of Bioenergy and Bioprocess Technology (QIBEBT) of the Chinese Academy of Sciences, the Beijing Chest Hospital, and the Qingdao Single-Cell Biotech has achieved a breakthrough in rapid antimicrobial susceptibility testing (AST) of RGM.